You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCalcium Acetate
Accession NumberDB00258  (APRD00839)
TypeSmall Molecule
GroupsApproved
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]

Structure
Thumb
Synonyms
Acetate OF lime
Brown acetate of lime
Ca(oac)2
calcium ethanoate
calcium(II) acetate
Gray acetate of lime
Lime acetate
Lime pyrolignite
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatecapsule667 mg/1oralSandoz Inc2012-03-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralClinical Solutions Wholesale2012-03-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralSandoz Inc2012-03-14Not applicableUs
Phoslocapsule667 mg/1oralCardinal Health2001-04-02Not applicableUs
Phoslocapsule667 mg/1oralPhysicians Total Care, Inc.2010-03-01Not applicableUs
Phoslocapsule667 mg/1oralFresenius Medical Care North America2001-04-02Not applicableUs
Phoslo Tabletstablet667 mgoralFresenius Medical Care North America2006-02-222013-07-29Canada
Phoslyrasolution667 mg/5mLoralFresenius Medical Care North America2011-04-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatetablet667 mg/1oralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium Acetatecapsule667 mg/1oralRoxane Laboratories, Inc2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralAv Kare, Inc.2015-04-092015-12-29Us
Calcium Acetatecapsule667 mg/1oralAmneal Pharmaceuticals of New York, LLC2014-10-08Not applicableUs
Calcium Acetatecapsule667 mg/1oralCardinal Health2013-07-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium Acetatecapsule667 mg/1oralExelan Pharmaceuticals, Inc.2014-04-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralCardinal Health2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralNostrum Laboratories, Inc.2015-10-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralMc Kesson Contract Packaging2013-04-09Not applicableUs
Calcium Acetatetablet667 mg/1oralZydus Pharmaceuticals USA Inc.2012-02-23Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralHeritage Pharmaceuticals Inc.2015-07-07Not applicableUs
Calcium Acetatecapsule667 mg/1oralZydus Pharmaceuticals USA Inc.2015-07-07Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralAtlantic Biologicals Corps2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralAv Pak2015-11-16Not applicableUs
Calcium Acetatecapsule667 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralGolden State Medical Supply, Inc.2015-12-22Not applicableUs
Calcium Acetatecapsule667 mg/1oralLupin Pharmaceuticals, Inc.2015-09-09Not applicableUs
Calcium Acetatecapsule667 mg/1oralREMEDYREPACK INC.2010-11-11Not applicableUs
Calcium Acetatetablet667 mg/1oralPaddock Laboratories, LLC2011-09-13Not applicableUs
Calcium Acetatecapsule667 mg/1oralLUPIN LIMITED2015-09-09Not applicableUs
Calcium Acetatetablet667 mg/1oralSafecor Health, LLC2014-08-15Not applicableUs
Calcium Acetatecapsule667 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Calcium Acetatecapsule667 mg/1oralAmerican Health Packaging2012-08-27Not applicableUs
Eliphostablet667 mg/1oralHawthorn Pharmaceutical, Inc.2009-02-01Not applicableUs
Eliphostablet667 mg/1oralCarilion Materials Management2009-02-01Not applicableUs
Eliphostablet667 mg/1oralKAISER FOUNDATION HOSPITALS2011-08-24Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetate Tab 667mgtablet667 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
TeltozanNot Available
Brand mixtures
NameLabellerIngredients
Aluminum Acetate AstringentTagi Pharma Incorporated
AstringentTAGI Pharma Inc.
DomeboroMOBERG PHARMA NORTH AMERICA LLC
Hyperlyte (multi-electrolyte Concentrate)B. Braun Medical Inc
LypholytePharmaceutical Partners Of Canada Inc
Lypholyte Multi-electrolyte Conc InjLyphomed, Division Of Fujisawa Canada Inc.
NutrilyteAmerican Regent, Inc.
Zo Medical Zo Post Procedure Recovery SystemZO Skin Health, Inc.
Salts
Name/CASStructureProperties
Calcium acetate monohydrate
ThumbNot applicableDBSALT001536
Categories
UNIIY882YXF34X
CAS number62-54-4
WeightAverage: 158.166
Monoisotopic: 157.989199835
Chemical FormulaC4H6CaO4
InChI KeyInChIKey=VSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentAcetate salts
Alternative Parents
Substituents
  • Acetate salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors
Pharmacology
IndicationCalcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
PharmacodynamicsPatients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of actionCalcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Related Articles
Absorption40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCalcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9462
CYP450 2C19 inhibitorNon-inhibitor0.9608
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral667 mg/1
Tabletoral667 mg
Powder, for solutiontopical
Tabletoral667 mg/1
Liquidintravenous
Solutionintravenous
Injection, solution, concentrateintravenous
Solutionoral667 mg/5mL
Kit
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6576665 No2001-04-032021-04-03Us
US6875445 No2001-07-302021-07-30Us
US8591938 No2010-02-232030-02-23Us
US8592480 No2007-07-202027-07-20Us
US9089528 No2007-07-202027-07-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point> 160 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility147.0 mg/mLALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Alan B. Gancy, “Process of making calcium acetate deicing agents and product.” U.S. Patent US4444672, issued November, 1946.

US4444672
General ReferencesNot Available
External Links
ATC CodesV03AE04V03AE07
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (25.6 KB)
MSDSDownload (72.9 KB)
Interactions
Drug Interactions
Drug
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.
AmphetamineCalcium Acetate may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Acetate.
BenzphetamineCalcium Acetate may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.
Calcium carbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcium Acetate.
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcium Acetate.
Calcium citrateThe risk or severity of adverse effects can be increased when Calcium citrate is combined with Calcium Acetate.
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcium Acetate.
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ceftriaxone.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Acetate.
DextroamphetamineCalcium Acetate may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DigoxinCalcium Acetate may increase the arrhythmogenic activities of Digoxin.
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Dihydrotachysterol.
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Acetate.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Acetate.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Acetate.
EphedrineThe serum concentration of Ephedrine can be increased when it is combined with Calcium Acetate.
EstramustineCalcium Acetate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Acetate.
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Acetate.
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Acetate.
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Acetate.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Acetate.
Lipoic AcidCalcium Acetate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
LisdexamfetamineCalcium Acetate may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Acetate.
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Calcium Acetate.
MemantineThe serum concentration of Memantine can be increased when it is combined with Calcium Acetate.
MethamphetamineCalcium Acetate may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Acetate.
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Acetate.
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium Acetate.
PerhexilineThe therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium Acetate.
PhendimetrazineCalcium Acetate may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
PhentermineCalcium Acetate may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Acetate.
PseudoephedrineThe serum concentration of Pseudoephedrine can be increased when it is combined with Calcium Acetate.
QuinineThe serum concentration of Quinine can be increased when it is combined with Calcium Acetate.
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Calcium Acetate.
SparfloxacinCalcium Acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Acetate.
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Acetate which could result in a lower serum level and potentially a reduction in efficacy.
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Acetate.
TriprolidineThe serum concentration of Triprolidine can be increased when it is combined with Calcium Acetate.
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.
Food InteractionsNot Available

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
binder
References
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. [PubMed:2811066 ]
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. [PubMed:12815333 ]
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. [PubMed:15882308 ]
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. [PubMed:15954948 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 01:52